Search results
Showing results for
Infinitopes, a clinical-stage cancer vaccine Biotechnology company, today announced the appointment of world-leading scientific innovator Dr Kristen Hege to its Scientific Advisory Board (SAB). This strategic appointment comes at a pivotal time after the launch of the VISTA trial, the first dosing in patients of Infinitopes’ lead precision cancer vaccine candidate, ITOP1. ITOP1 is a therapeutic vaccine designed to prevent recurrence in oesophageal cancer – a major area of unmet clinical need.
